SLC5A2 and hydrops fetalis: A prospective, double-blind, placebo-controlled, parallel-group single-center trial comprising 72 patients with HF (LVEF 39.0 ± 8.2%) randomly allocated (2:1) to the SGLT-2 inhibitor empagliflozin 10 mg orally qd or to placebo, who finished the study, showed that ketone body levels as represented by beta-hydroxybutyrate (β-OHB) concentrations rose after therapy with empagliflozin [57].